Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
© The Author 2015. Background. Concomitant use of rifamycins to treat or prevent tuberculosis can result in subtherapeutic concentrations of antiretroviral drugs. We studied the interaction of efavirenz with daily rifapentine and isoniazid in human immunodeficiency virus (HIV)-infected individuals r...
Saved in:
Main Authors: | Anthony T. Podany, Yajing Bao, Susan Swindells, Richard E. Chaisson, Janet W. Andersen, Thando Mwelase, Khuanchai Supparatpinyo, Lerato Mohapi, Amita Gupta, Constance A. Benson, Peter Kim, Courtney V. Fletcher |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84943232683&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44134 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
by: Anthony T. Podany, et al.
Published: (2018) -
One month of rifapentine plus isoniazid to prevent HIV-related Tuberculosis
by: Susan Swindells, et al.
Published: (2019) -
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
by: Jyoti S. Mathad, et al.
Published: (2022) -
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women
by: Mathad J.S.
Published: (2023) -
A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens
by: Nontiya Homkham, et al.
Published: (2018)